Beyond topoisomerase II inhibition, etoposide-quinone (metabolite of the drug) is known to impair the activity of CREBBP (acetyltransferase enzyme also with tumour suppressor functions) (53) herein potentially increasing the risk of additional molecular anomalies that increase even further the neoplastic phenotypic aggressiveness. This evidence concerns the gene CREBBP and neoplasm.